Clinical trial adaptation by matching evidence in complementary patient subgroups of auxiliary blinding questionnaire responses

PLoS ONE

Volumn 10, Issue 7, 2015, Pages

  Arandjelović, Ognjen ^a  

^a DEAKIN UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; AUXILIARY BLINDING QUESTIONNAIRE; CLINICAL EFFECTIVENESS; CLINICAL PROTOCOL; CLINICAL TRIAL (TOPIC); CLINICAL TRIAL ADAPTATION; CONCEPTUAL FRAMEWORK; DATA ANALYSIS; HUMAN; INFORMATION PROCESSING; MATHEMATICAL COMPUTING; QUESTIONNAIRE; SAMPLE SIZE; STATISTICAL MODEL; ALGORITHM; BIOSTATISTICS; METHODOLOGY; PATIENT SELECTION; PROCEDURES; REPRODUCIBILITY; STATISTICS AND NUMERICAL DATA;

ALGORITHMS; BIOSTATISTICS; CLINICAL TRIALS AS TOPIC; HUMANS; PATIENT SELECTION; REPRODUCIBILITY OF RESULTS; RESEARCH DESIGN; SAMPLE SIZE;

EID: 84941362383     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0131524     Document Type: Article

References (52)

1. Meinert CL. Clinical Trials: Design, Conduct, and Analysis. 3rd ed. New York, New York: Oxford University Press; 1986.
2. Piantadosi S. Clinical Trials: A Methodologic Perspective. 3rd ed. Hoboken, New Jersey: Wiley; 1997.
3. Friedman L, Furberg C, DeMets D. Fundamentals of Clinical Trials. 3rd ed. New York, New York: Springer-Verlag; 1998.
4. Penston J. Large-scale randomised trials-a misguided approach to clinical research. Med Hypotheses. 2005; 64(3):651-657. doi: 10.1016/j.mehy.2004.09.006 PMID: 15617882
5. Fisher LD. Self-designing clinical trials. Stat Med. 1998; 17:1551-1562. doi: 10.1002/(SICI)1097-0258 (19980730)17:14%3C1551::AID-SIM868%3E3.0.CO;2-E PMID: 9699229
6. U S Department of Health and Human Services. Guidance for Industry: Adaptive Design Clinical Trials for Drugs and Biologics. Food and Drug Administration Draft Guidance. 2010 Feb;.
7. Hung HMJ, Wang SJ, ONeill RT. Methodological issues with adaptation of clinical trial design. Pharmaceut Statist. 2006; 5:99-107. doi: 10.1002/pst.219
8. Orloff J, Douglas F, Pinheiro J, Levinson S, Branson M, Chaturvedi P, et al. The future of drug development: advancing clinical trial design. Nat Rev Drug Discov. 2009; 8(12):949-957. PMID: 19816458
9. Berry DA. Adaptive clinical trials: the promise and the caution. J Clin Oncol. 2011; 29(6):606-609. doi: 10.1200/JCO.2010.32.2685 PMID: 21172875
10. Chow SC, Chan M. Adaptive Design Methods in Clinical Trials. Chapman & Hall; 2011.
11. Cui L, Hung HMJ, Wang SJ. Modification of sample size in group sequential clinical trials. Biometrics. 1999; 55:321-324.
12. Nissen SE. ADAPT: The Wrong Way to Stop a Clinical Trial. PLoS Clin Trials. 2006; 1(7):e35. doi: 10. 1371/journal.pctr.0010035 PMID: 17111045
13. Lang T. Adaptive trial design: could we use this approach to improve clinical trials in the field of global health? Am J Trop Med Hyg. 2011; 85(6):967-970.
14. Arandjelović O. Sample-targeted clinical trial adaptation. Proc Conf AAAI Artif Intell. 2015; 3:1693-1699.
15. Arandjelović O. Assessing blinding in clinical trials. Adv Neural Inf Proc Sys. 2012; 25:530-538.
16. Arandjelović O. A new framework for interpreting the outcomes of imperfectly blinded controlled clinical trials. PLOS ONE. 2012; 7(12):e48984. doi: 10.1371/journal.pone.0048984 PMID: 23236350
17. Haahr MT, Hróbjartsson A. Who is blinded in randomized clinical trials? A study of 200 trials and a survey of authors. Clin Trials. 2006; 3(4):360-365. PMID: 17060210
18. Berry SM, Carlin BP, Lee JJ, Müller P. Bayesian adaptive methods for clinical trials. CRC Press; 2010.
19. Kadane JB, editor. Bayesian methods and ethics in a clinical trial design. John Wiley & Sons; 2011.
20. Lawson AB. Bayesian disease mapping: hierarchical modeling in spatial epidemiology. CRC Press; 2013.
21. Oniško A, Druzdzel MJ. Impact of precision of Bayesian network parameters on accuracy of medical diagnostic systems. Artif Intell Med. 2013; 57(3):197-206. doi: 10.1016/j.artmed.2013.01.004 PMID: 23466438
22. Gelman A, Carlin JB, Stern HS, Rubin DB. Bayesian data analysis. Chapman & Hall/CRC; 2014.
23. Spiegelhalter DJ, Abrams KR, Myles JP. Bayesian approaches to clinical trials and health-care evaluation. John Wiley & Sons; 2004.
24. Berry DA. Bayesian clinical trials. Nat Rev Drug Discov. 2006; 5:27-36. doi: 10.1038/nrd1927 PMID: 16485344
25. Chen MH, Dey DK, Müller P, Sun D, Ye K. Bayesian clinical trials. In: Frontiers of Statistical Decision Making and Bayesian Analysis. Springer; 2010. p. 257-284.
26. Lee JJ, Chu CT. Bayesian clinical trials in action. Stat Med. 2012; 31(25):2955-2972. doi: 10.1002/sim. 5404 PMID: 22711340
27. Berry DA. Adaptive clinical trials in oncology. Nat Rev Clin Oncol. 2012; 9(4):199-207. doi: 10.1038/ nrclinonc.2011.165
28. Yin G. Clinical trial design: Bayesian and frequentist adaptive methods. John Wiley & Sons; 2013.
29. Broglio KR, Connor JT, Berry SM. Not too big, not too small: A Goldilocks approach to sample size selection. JJ Biopharm StatBiopharm Stat. 2014; 24(3):685-705. doi: 10.1080/10543406.2014.888569
30. Gao P, Ware JH, Mehta C. Sample size re-estimation for adaptive sequential design in clinical trials. J Biopharm Stat. 2008; 18:1184-1196. doi: 10.1080/10543400802369053 PMID: 18991116
31. Leon AC. Implications of clinical trial design on sample size requirements. Schizophr Bull. 2008; 34 (4):664-669. doi: 10.1093/schbul/sbn035 PMID: 18469326
32. Zang Y, Lee JJ. Adaptive clinical trial designs in oncology. Chin Clin Oncol. 2014; 3(4):49.
33. Jennison C, Turnbull BW. Mid-course sample size modification in clinical trials based on the observed treatment effect. Stat Med. 2003; 22(6):971-993. doi: 10.1002/sim.1457 PMID: 12627413
34. James KE, Bloch DA, Lee KK, Kraemer HC, Fuller RK. An index for assessing blindness in a multi-centre clinical trial: disulfiram for alcohol cessation-a VA cooperative study. Stat Med. 1996; 15(13):1421-1434. doi: 10.1002/(SICI)1097-0258(19960715)15:13%3C1421::AID-SIM266%3E3.0.CO;2-H PMID: 8841652
35. Bang H, Ni L, Davis CE. Assessment of blinding in clinical trials. Contemp Clin Trials. 2004; 25(2): 143-156. doi: 10.1016/j.cct.2003.10.016
36. Hróbjartsson A, Forfang E, Haahr MT, Als-Nielsen B, Brorson S. Blinded trials taken to the test: an analysis of randomized clinical trials that report tests for the success of blinding. Int J Epidemiol. 2007; 36 (3):654-663. doi: 10.1093/ije/dym020 PMID: 17440024
37. Kolahi J, Bang H, Park J. Towards a proposal for assessment of blinding success in clinical trials: upto- date review. Community Dent Oral Epidemiol. 2009; 37(6):477-484. doi: 10.1111/j.1600-0528.2009. 00494.x PMID: 19758415
38. Sackett DL. Commentary: Measuring the success of blinding in RCTs: don't, must, can't or needn't? Int J Epidemiol. 2007; 36(3):664-665. PMID: 17675306
39. Hemilä H. Assessment of blinding may be inappropriate after the trial. Contemp Clin Trials. 2005; 26 (4):512-514. doi: 10.1016/j.cct.2005.04.004 PMID: 15951244
40. Henneicke-von Zepelin HH. Letter to the Editor. Contemp Clin Trials. 2005; 26(4):512. doi: 10.1016/j. cct.2005.04.004 PMID: 15936250
41. Wickens CD. Engineering Psychology and Human Performance. 2nd ed. New York: Harper Collins Publishers Inc.; 1992.
42. Berger V. Selection Bias and Covariate Imbalances in Randomized Clinical Trials. Hoboken, New Jersey: Wiley; 2005.
43. Biswas S, Liu DD, Lee JJ, Berry DA. Bayesian clinical trials at the University of Texas MD Anderson cancer center. Clin Trials. 2009; 6(3):205-216. doi: 10.1177/1740774509104992 PMID: 19528130
44. Nelson NJ. Adaptive Clinical Trial Design: Has Its Time Come? JNCI J Natl Cancer Inst. 2010; 102 (16):1217-1218.
45. Meurer WJ, Lewis RJ, Tagle D, Fetters MD, Legocki L, Berry S, et al. An overview of the adaptive designs accelerating promising trials into treatments (ADAPT-IT) project. Ann Emerg Med. 2012; 60 (4):451-457. doi: 10.1016/j.annemergmed.2012.01.020 PMID: 22424650
46. Kullback RA, Leibler S. On Information and Sufficiency. Ann Math Stat. 1951; 22(1):79-86. doi: 10. 1214/aoms/1177729694
47. Bhattacharyya A. On a measure of divergence between two statistical populations defined by their probability distributions. Bull Calcutta Math Soc. 1943; 35:99-109.
48. Hellinger E. Neue Begründung der Theorie quadratischer Formen von unendlichvielen Veränderlichen. J Reine Angew Math. 1909; 136:210-271.
49. Gilks WR. Markov Chain Monte Carlo in Practice. 1st ed. Chapman and Hall/CRC; 1995.
50. Aitchison J, Brown JAC. The Lognormal Distribution. Cambridge University Press; 1957.
51. Ly LP, Jimenez M, Zhuang TN, Celermajer DS, Conway AJ, Handelsman DJ. A double-blind, placebocontrolled, randomized clinical trial of transdermal dihydrotestosterone gel on muscular strength, mobility, and quality of life in older men with partial androgen deficiency. J Clin Endocrinol Metab. 2001; 86 (9):4078-4088. doi: 10.1210/jcem.86.9.7821 PMID: 11549629
52. Cohen SB, Dore RK, Lane NE, Ory PA, Peterfy CG, Sharp JT, et al. Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: A twelve-month, multicenter, randomized, double-blind, placebo-controlled, phase II clinical trial.. Arthritis Rheum. 2008; 58(5):1299-1309. doi: 10.1002/art.23417 PMID: 18438830